ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 110 filers reported holding ARBUTUS BIOPHARMA CORP in Q4 2023. The put-call ratio across all filers is 0.92 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $47,116 | +48.4% | 15,248 | +23.9% | 0.00% | – |
Q1 2024 | $31,755 | +3.2% | 12,308 | 0.0% | 0.00% | – |
Q4 2023 | $30,771 | +23.2% | 12,308 | 0.0% | 0.00% | – |
Q3 2023 | $24,985 | -22.7% | 12,308 | -12.4% | 0.00% | – |
Q2 2023 | $32,332 | -12.5% | 14,057 | +15.2% | 0.00% | – |
Q1 2023 | $36,960 | +30.0% | 12,198 | 0.0% | 0.00% | – |
Q4 2022 | $28,421 | +23.6% | 12,198 | 0.0% | 0.00% | – |
Q3 2022 | $23,000 | -17.9% | 12,198 | +16.5% | 0.00% | – |
Q2 2022 | $28,000 | +16.7% | 10,466 | +31.6% | 0.00% | – |
Q1 2022 | $24,000 | -4.0% | 7,951 | +21.9% | 0.00% | – |
Q4 2021 | $25,000 | -10.7% | 6,525 | 0.0% | 0.00% | – |
Q3 2021 | $28,000 | +47.4% | 6,525 | +4.6% | 0.00% | – |
Q2 2021 | $19,000 | +72.7% | 6,241 | +18.9% | 0.00% | – |
Q2 2019 | $11,000 | -42.1% | 5,247 | 0.0% | 0.00% | – |
Q1 2019 | $19,000 | -82.6% | 5,247 | -81.5% | 0.00% | – |
Q4 2018 | $109,000 | -53.0% | 28,407 | +15.8% | 0.00% | – |
Q3 2018 | $232,000 | +510.5% | 24,540 | +367.7% | 0.00% | – |
Q2 2018 | $38,000 | – | 5,247 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 2,651,825 | $19,358,000 | 6.60% |
RTW INVESTMENTS, LP | 5,165,499 | $37,708,000 | 2.72% |
Eversept Partners, LP | 97,495 | $711,714 | 0.33% |
Seelaus Asset Management LLC | 14,300 | $104,000 | 0.09% |
LADENBURG THALMANN FINANCIAL SERVICES INC. | 1,765,315 | $8,827,000 | 0.08% |
ALGERT GLOBAL LLC | 34,816 | $254,000 | 0.05% |
BOOTHBAY FUND MANAGEMENT, LLC | 48,000 | $350,000 | 0.03% |
OXFORD ASSET MANAGEMENT LLP | 211,115 | $1,540,000 | 0.03% |
PRIMECAP MANAGEMENT CO/CA/ | 4,000,400 | $29,203,000 | 0.02% |
PDT Partners, LLC | 66,965 | $489,000 | 0.02% |